Anavex Life Sciences (NASDAQ:AVXL – Get Free Report) announced its quarterly earnings results on Tuesday. The biotechnology company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.01, Yahoo Finance reports. During the same period last year, the company posted ($0.14) EPS.
Anavex Life Sciences Stock Down 0.8 %
NASDAQ AVXL traded down $0.05 during trading on Friday, hitting $6.59. The company’s stock had a trading volume of 27,501 shares, compared to its average volume of 1,318,052. Anavex Life Sciences has a 52 week low of $3.25 and a 52 week high of $10.45. The firm has a market cap of $557.79 million, a P/E ratio of -13.28 and a beta of 0.63. The firm has a 50 day moving average price of $4.97 and a 200 day moving average price of $4.87.
Analysts Set New Price Targets
Several analysts recently issued reports on AVXL shares. EF Hutton Acquisition Co. I raised shares of Anavex Life Sciences to a “strong-buy” rating in a report on Monday, July 22nd. HC Wainwright restated a “buy” rating and set a $40.00 price target on shares of Anavex Life Sciences in a report on Thursday, August 1st.
About Anavex Life Sciences
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.
Featured Articles
- Five stocks we like better than Anavex Life Sciences
- With Risk Tolerance, One Size Does Not Fit All
- Why Analysts Still Predict Double-Digit Upside for Mosaic Stock
- How to Invest in the Best Canadian StocksĀ
- Novo Nordisk’s Shares Go on a Rollercoaster Ride After Earnings
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Wall Street Predicts Zillow Stock Will Dominate in Performance
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.